Please join us for a historic interactive exchange between Dr. Carl June, the pioneer of chimeric antigen receptor (CAR) T cell therapy, and Dr. Georg Schett, the pioneer of CAR T cell therapy as applied to the treatment of autoimmune diseases. Dr. Schett sparked the movement of CAR T in autoimmune diseases through his use of thetechnology to benefit patients with systemic lupus erythematosus, myositis and systemic sclerosis. Over the prior decades, Dr. June led the research team that discovered and developed the first approved CAR T cell therapy in oncology, tisagenlecleucel (Kymriah®, Novartis). The session will be moderated by Dr. David Chang, FACR, the Chief Medical Officer of Cabaletta Bio, who oversaw the development of the only two products approved for systemic lupus erythematosus in the U.S. in over 60 years. Cabaletta is a clinical-stage biotechnology company focused on developing and launching engineered T cell therapies with potential to provide a deep and durable, perhaps curative, treatment for patients with autoimmune diseases. Cabaletta is currently advancing Phase 1/2 clinical trials in systemic lupus erythematosus and myositis with CABA-201, a fully human CD19-CAR T containing a 4-1BB co-stimulatory domain. The audience will gain insights into the development of CD19-CAR T cell therapy, the rationale for applying this technology to autoimmune diseases and the anticipated patient outcomes. Further, the panel will discuss the potential of CD19-CAR T cell therapies in providing durable responses off therapy to patients with autoimmune diseases. Developed and offered by Cabaletta Bio.
Non-CME
